Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy.
OBJECTIVE
To report the use of wide-area 5-aminolevulinic acid photodynamic therapy to treat numerous basal cell carcinomas (BCCs) and basaloid follicular hamartomas (BFHs).


METHODS
Report of cases.


METHODS
Roswell Park Cancer Institute. Patients Three children with BCCs and BFHs involving 12% to 25% of their body surface areas. Interventions Twenty percent 5-aminolevulinic acid was applied to up to 22% of the body surface for 24 hours under occlusion. A dye laser and a lamp illuminated fields up to 7 cm and 16 cm in diameter, respectively; up to 36 fields were treated per session.


METHODS
Morbidity, patient response, and light dose-photodynamic therapy response relationship and durability.


RESULTS
Morbidity was minimal, with selective phototoxicity and rapid healing. After 4 to 7 sessions, with individual areas receiving 1 to 3 treatments, the patients had 85% to 98% overall clearance and excellent cosmetic outcomes without scarring. For laser treatments, a sigmoidal light dose-response relationship predicted more than 85% initial response rates for light doses 150 J/cm(2) or more. Responses were durable up to 6 years. Conclusion 5-Aminolevulinic acid photodynamic therapy is safe, well tolerated, and effective for extensive areas of diffuse BCCs and BFHs and appears to be the treatment of choice in children.
Oseroff
Allan R
AR
Department of Dermatology, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY 14263, USA. allan.oseroff@roswellpark.org
Shieh
Sherry
S
Frawley
Noreen P
NP
Cheney
Richard
R
Blumenson
Leslie E
LE
Pivnick
Eniko K
EK
Bellnier
David A
DA
D000293:Adolescent; D000622:Aminolevulinic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D005260:Female; D006223:Hamartoma Syndrome, Multiple / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D010778:Photochemotherapy / Q000009:adverse effects; D017319:Photosensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid